A macrocyclic peptide containing a phosphotyrosyl mimetic achieved potent binding to the Grb2 SH2 domain — a critical cancer signaling hub — demonstrating macrocyclic drug design for disrupting cancer growth pathways.
Cancer hub targetedMacrocyclic design achieved potent binding to Grb2 SH2 — a cancer signaling hub that conventional small molecules struggle to block
What the researchers found
A macrocyclic peptide incorporating beta-aminophosphotyrosyl mimetic achieved potent Grb2 SH2 domain binding through conformational restriction, demonstrating macrocyclic drug design for cancer signaling disruption.
Why it matters
Protein-protein interactions drive cancer but are notoriously difficult drug targets. Macrocyclic peptides can achieve the large binding surfaces needed to disrupt these interactions — a key cancer drug design strategy.
How the study worked
In-vitro study. Macrocyclic peptide designed with phosphotyrosyl mimetic for Grb2 SH2 binding. Binding affinity measured by surface plasmon resonance. Comparison to linear counterparts.
What this study cannot tell us
In-vitro binding only. Cell-based activity and in-vivo efficacy not demonstrated. Oral bioavailability of macrocyclic phosphopeptide mimetics is challenging.
How to read the evidence
Preliminary in-vitro binding evidence demonstrating a viable macrocyclic approach to a challenging cancer drug target.
When this study was published
Published in 2003. Macrocyclic drugs targeting protein-protein interactions in cancer have advanced significantly.
The bigger picture
Protein-protein interaction inhibitors are the next frontier in cancer drugs. Macrocyclic peptides can achieve what small molecules cannot — disrupting the large, flat binding surfaces where cancer proteins communicate.
Questions still open
- Can macrocyclic Grb2 inhibitors achieve cell penetration?
- Would this approach work for other cancer SH2 domain targets?
- Could oral delivery be achieved through further macrocycle optimization?
Common questions
Why is cancer signaling hard to block with drugs?
Could this become a cancer drug?
Read the original research
Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
Journal of medicinal chemistry, 46(13), 2621-30
Citation
Lee, Kyeong; Zhang, Manchao; Liu, Hongpeng; Yang, Dajun; Burke, Terrence R. (2003). Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.. Journal of medicinal chemistry, 46(13), 2621-30.